



Market in a Minute

August 18, 2026

Index Performance: As of August 14, 2026

Index	Price	Last Week	YTD
S&P 500	7,785.76	0.36%	13.74%
Dow Jones	53,732.41	-0.56%	11.80%
NASDAQ	26,729.16	0.14%	15.00%
Russell 2000	16,934.18	1.15%	24.47%
Russell 2000 Growth	14,948.45	1.42%	22.04%
Russell 2000 Value	25,018.85	0.86%	25.19%
Russell 1000 Growth Total Return	5,250.89	0.52%	5.50%
SPDR Gold Shares	401.48	0.76%	1.30%
Powershares US \$ Index	28.11	0.14%	4.00%
iShares EAFE Index	108.64	0.08%	13.13%
Barclays Aggregate Bond Index	97.48	-0.12%	-2.40%
iShares Barclays 20+ Yr Treasury Bond	82.04	-0.87%	-5.87%
Utilities Select Sector ETF	44.31	1.61%	3.79%
Vanguard REIT ETF	98.83	0.41%	11.68%
iShares Mortgage Real Estate	22.12	0.59%	-0.27%
Alerian MLP ETF	54.96	1.10%	16.89%
iShares Global Telecom	118.03	0.03%	-2.63%
ETFMG Alternative Harvest ETF	24.99	5.58%	-16.11%
Grayscale Bitcoin Trust	48.68	-3.22%	-28.79%
Shanghai SE Index	3,927.18	-0.33%	-1.05%

A Word on the Market

By: Patrick Adams, CFA



Market Update:

- The probability of a rate increase by the Federal Reserve has dropped to about 33% in September, as we expected the rate increase would not occur. We got our expected modest inflation report, which was 2.5% Core Inflation, we strongly do not believe the Fed will increase rates in September.
- As a result, the 10-Year Treasury went above 4.7% recently, which reflects the bond market seeing the economy continue to be fine and the Fed allowing growth. We would be very concerned if the 10-Year spiked above 5% and the resulting negative impact on the stock market. There is tremendous supply of bonds from the technology sector pushing rates up.
- Many strategists have pushed their price targets up for the S&P 500, due to strong earnings, by year-end.
 - JP Morgan year-end 8,000
 - Goldman Sachs 8,000
 - Ed Yardeni 8,400
 - Tom Lee 8,000, but with a significant decline before year-end.
 - Morgan Stanley 8,000
 - RBC 8,150 over 12 months
 - Bank of America 7,100
- What stands out is Tom Lee's pullback, we follow his work as he is right a lot and does not seem to be a Perma Bull or Bear.
- The other target from Bank of America is worth investigating here is their reasoning:

Source: Bloomberg & Yahoo.com, Returns are appreciation only.

S&P Sector Performance: As of Aug 14, 2026			
Index	Price	Last Week	YTD
Information Technology	7,042.54	0.22%	23.90%
Consumer Disc.	1,937.95	-1.97%	0.49%
Consumer Staples	950.67	0.99%	9.92%
Health Care	1,949.46	0.98%	7.95%
Financials	966.56	0.90%	6.03%
Industrials	186.51	0.72%	20.24%
Energy	946.99	7.31%	37.78%
Communications Services	458.02	-0.96%	1.24%
Utilities	449.01	1.45%	3.50%
Materials	656.65	-0.87%	14.32%
Real Estate	288.15	0.66%	12.99%

Source: Bloomberg website, Returns are appreciation only

PVG Strategies			
Tactical Strategies	QTD	YTD	Average Annual Return as of 6/30/26
Tactical Total Return	1.82%	-1.29%	9.53%
Dynamic Core	3.24%	-0.48%	9.87%
Tactical Growth	2.67%	-7.75%	19.33%
Absolute Balanced			
Loss Averse			
Loss Averse Equity Income	1.35%	2.87%	4.51%
Specialty			
Emerging Healthcare	0.13%	-16.66%	64.91%
Focus			
High Income Focus 10	0.04%	2.18%	7.22%
Growth Focus 10	-0.81%	-8.89%	13.78%

- High price-to-earning stocks are outperforming low
 - Valuation of the S&P 500 is stretched
 - Lofty growth expectations
 - Narrow market breadth
 - Credit and Market stress, meaning declining consumer confidence and tighter lending standards
- We have our own strong views and if you remember our target has been 7850 for a while. We have been looking for volatility like we saw in the first half when we had that roughly -10% pullback. If you remember we took advantage of that decline earlier in the year. We think as we get closer to the mid-term elections the high P/E stocks could fall meaningfully.
 - As the market approaches the second quarter of 2027 the earnings comparisons are going to be much harder, and the momentum trade will get very difficult. This could spark a large pullback.

S&P 500 Range of Targets 8,400-7,100



Biotechnology:

- CAPR has a drug that reported very strong results for Duchesne Muscular Dystrophy (DMD). With these results back in November 2025, the stock had a roughly 10x move in a day. That was fun!!!
- The stock imploded on news from the FDA recently, the FDA believes among other issues that the results were not as good and actually failed if an old scale to measure results were used.

Emerging Healthcare Focus 10	-0.57%	-24.87%	12.36%
Strategic			
Tactical Aggressive	1.03%	-4.05%	15.15%
Tactical Moderate	1.44%	-2.26%	12.00%
Tactical Conservative	0.99%	2.17%	8.88%
Tactical Income	0.37%	1.42%	7.83%


Interest Rates			
Fed Fund	3.63 %	5-Year	4.32%
3-Month	3.87%	10-Year	4.63%
6-Month	3.94%	30-Year	5.21%
2-Year	4.15%		

Source: Bloomberg.com

Economic Events This Week			
Date	Report	Forecast	Previous
Aug 18	Housing Starts	1360K	1427K
Aug 18	Building Permits	1390K	1367K
Aug 18	Industrial Production	0.3%	76.1%
Aug 18	Capacity Utilization	76.3%	76.1%
Aug 18	Pending Home Sales	1.3%	-5.4%
Aug 20	Philadelphia Fed Index	25.0	41.4
Aug 20	Leading Economic Index	-0.1%	-0.2%

Economic Events Last Week	
August 11	Existing Home sales held steady around 4.1 million annualized

- The FDA seems to have pushed the advisory committee to vote 9-3 against approval, and then the stock traded below cash of \$4.00
- It appears now there may be a compromise brewing which could lift the stock. Below \$4.00 this seems to be a one direction outcome.
- In our opinion, this drug should get conditional approval provided the company agrees to do a confirmatory trial. It is a small patient population and can be easily monitored. There is no other drug for DMD and the outcome of the disease is fatal.



August 12	CPI rose 0.1% MoM and 3.4% YoY
August 13	PPI was flat MoM & Core PPI rose 0.2%
August 14	University of Michigan Consumer Sentiment dropped to 51

There are no warranties, expressed or implied as to the accuracy, completeness, or results obtained from any information provided herein or on the material provided. This document does not constitute a complete description of our investment services and is for informational purposes only. It is in no way a solicitation or an offer to sell securities or investment advisory services. Any statements regarding market or other financial information is obtained from sources which we believe to be reliable, but we do not warrant or guarantee the timeliness or accuracy of this information. Neither our information providers nor we shall be liable for any errors or inaccuracies, regardless of cause, or the lack of timeliness of, or for any delay or interruption in the transmission thereof to the user. All investments involve risk, including foreign currency exchange rates, political risks, market risk, different methods of accounting and financial reporting, and foreign taxes. All performance results have been compiled solely by PVG Asset Management and have not been independently verified. To be a client of PVG you must sign an investment advisory agreement, review our ADV, Form CRS and privacy policy. For performance and risk information on any strategy it is contained in the specific tear sheet of the strategy, along with important disclosures. We will also desire to answer your questions on our strategies. Hypothetical or simulated performance results have certain limitations. Unlike an actual performance record, simulated results do not represent actual trading. No representation is being made that any account will or is likely to achieve profit or losses similar to those shown. It should not be assumed that investors who actually invest in the adviser's strategies will be profitable or achieve the hypothetical performance results reflected or any corresponding index presented. Weights and allocations are subject to change. Please see our website for complete performance for each strategy, the performance record for each strategy displayed on this weekly update is not intended to display a complete history due to available room on this report. Do not invest without reviewing the tear sheets, ADV, Form CRS, and talking with our portfolio managers to make sure these strategies fit your risk profile.